TY  - JOUR
T1  - Cardiovascular and Metabolic Risk Profiles Across Different Phenotypes of Polycystic Ovary Syndrome
TT  - Polikistik Over Sendromu Fenotipleri Arasında Kardiyovasküler ve Metabolik Risk Profillerinin Karşılaştırılması
AU  - Aksu, Erson
AU  - Gül, Abdulaziz
PY  - 2025
DA  - November
Y2  - 2025
DO  - 10.16899/jcm.1794476
JF  - Journal of Contemporary Medicine
JO  - J Contemp Med
PB  - Rabia YILMAZ
WT  - DergiPark
SN  - 2667-7180
SP  - 307
EP  - 314
VL  - 15
IS  - 6
LA  - en
AB  - Aim: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder affecting 5–10% of women of reproductive age and is increasingly recognized as a female-specific cardiometabolic condition. Although metabolic risk factors such as insulin resistance, dyslipidemia, and hypertension are well established in PCOS, their distribution across distinct phenotypes remains controversial.Material and Methods: In this retrospective study, 240 women diagnosed with PCOS based on the 2003 Rotterdam criteria and 116 healthy controls aged 18–42 years were evaluated. Patients with PCOS were categorized into four phenotypes: (i) hyperandrogenism + oligo/anovulation + polycystic ovaries (HA+OA+PCO), (ii) hyperandrogenism + oligo/anovulation (HA+OA), (iii) hyperandrogenism + polycystic ovaries (HA+PCO), and (iv) polycystic ovaries + oligo/anovulation (PCO+OA). Anthropometric measurements, hormonal profiles, lipid panels, glucose-insulin parameters, and HOMA-IR indices were compared between groups.Results: Compared with controls, women with PCOS had significantly higher triglycerides, fasting insulin, HOMA-IR, total testosterone, DHEAS, and LH/FSH ratio, while HDL cholesterol was lower (all p
KW  - Polycystic ovary syndrome
KW  - phenotypes
KW  - insulin resistance
KW  - cardiovascular risk;
KW  - metabolic syndrome
N2  - Amaç: Polikistik over sendromu (PCOS), üreme çağındaki kadınların %5–10’unu etkileyen heterojen bir endokrin bozukluktur ve giderek kadınlara özgü bir kardiyometabolik durum olarak tanınmaktadır. İnsülin direnci, dislipidemi ve hipertansiyon gibi metabolik risk faktörleri PCOS’ta iyi tanımlanmış olsa da, bunların farklı fenotipler arasındaki dağılımı tartışmalıdır.Gereç ve Yöntem: Bu retrospektif çalışmada, 2003 Rotterdam kriterlerine göre PCOS tanısı almış 240 kadın ve 18–42 yaş aralığında 116 sağlıklı kontrol değerlendirildi. PCOS’lu hastalar dört fenotipe ayrıldı: (i) hiperandrojenizm + oligo/anovulasyon + polikistik overler (HA+OA+PCO), (ii) hiperandrojenizm + oligo/anovulasyon (HA+OA), (iii) hiperandrojenizm + polikistik overler (HA+PCO), (iv) polikistik overler + oligo/anovulasyon (PCO+OA). Gruplar arasında antropometrik ölçümler, hormonal profiller, lipid panelleri, glukoz-insülin parametreleri ve HOMA-IR indeksleri karşılaştırıldı.Bulgular: Kontrollerle karşılaştırıldığında, PCOS’lu kadınlarda trigliserid, açlık insülini, HOMA-IR, total testosteron, DHEAS ve LH/FSH oranı anlamlı derecede yüksek; HDL kolesterol ise daha düşüktü (tümü p
CR  - 1-	Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261-71.
CR  - 2-	Melson E, Davitadze M, Malhotra K, Mousa A, Teede H, Kempegowda P, et al. A systematic review of models of care for polycystic ovary syndrome highlights the gap in the literature, especially in developing countries. Front Endocrinol (Lausanne). 2023;14:1217468.
CR  - 3-	Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-18.
CR  - 4-	Carmina E, Nasrallah MP, Guastella E, Lobo RA. Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clin Endocrinol (Oxf). 2019;91(4):553-60.
CR  - 5-	Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42-52.
CR  - 6-	Luque-Ramírez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr Hypertens Rep. 2014;16(12):500.
CR  - 7-	Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477-88.
CR  - 8-	Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88(5):1389-95.
CR  - 9-	Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197-201.
CR  - 10-	Wiltgen D, Spritzer PM. Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2493-6.
CR  - 11-	Matthews D.R. et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412–419.
CR  - 12-	Radikova Z. et al. (2006). Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes, 114(5): 249–256.
CR  - 13-	Barrea L, Frias-Toral E, Verde L, Ceriani F, Cucalón G, Garcia-Velasquez E, et al. PCOS and nutritional approaches: differences between lean and obese phenotype. Metab Open. 2021;12:100123.
CR  - 14-	Tosi F, Di Sarra D, Kaufman JM, Bonin C, Moretta R, Bonora E, et al. Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(2):661-9.
CR  - 15-	Jurczewska J, Ostrowska J, Chełchowska M, Panczyk M, Rudnicka E, Kucharski M, et al. Abdominal obesity in women with polycystic ovary syndrome and its relationship with diet, physical activity and insulin resistance: a pilot study. Nutrients. 2023;15(16):3652.
CR  - 16-	Dadachanji R, Patil A, Joshi B, Mukherjee S. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS One. 2021;16(2):e0246862.
CR  - 17-	Akkus C, Oner O, Kilic AO, Duran C. Visceral adiposity index (VAI) levels and metabolic risk across phenotypes of polycystic ovary syndrome (PCOS). Medicina. 2025;61(9):1673.
CR  - 18-	Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137-42.
CR  - 19-	Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3):1073-9.
CR  - 20-	Spritzer PM, Ramos RB, Marchesan LB, de Oliveira M, Carmina E. Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):18.
CR  - 21-	Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607-13.
CR  - 22-	Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2018;86:33-43.
CR  - 23-	Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 2007;49(6):1442-7.
CR  - 24-	Tuorila K, Ollila MM, Hurskainen E, Tapanainen J, Franks S, Piltonen T, et al. Association of hyperandrogenaemia with hypertension and cardiovascular events in pre-menopausal women: a prospective population-based cohort study. Eur J Endocrinol. 2024;191(4):433-43.
CR  - 25-	Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020;18(1):23.
CR  - 26-	Geraci G, Riccio C, Oliva F, Gabrielli D, Colivicchi F, Grimaldi M, et al. Women with PCOS have heightened risk of cardiometabolic and cardiovascular diseases. Statement from Expert Group On Inositol in basic and clinical research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologist (ANMCO). Front Cardiovasc Med. 2025;12:1520490.
CR  - 27-	Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453-62.
CR  - 28-	Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, et al. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine. 2014;47(2):631-8.
CR  - 29-	Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520.
CR  - 30-	Su P, Chen C, Sun Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. J Ovarian Res. 2025;18(1):34.
CR  - 31-	Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2248-56.
CR  - 32-	Pratama G, Wiweko B, Asmarinah, Widyahening IS, Andraini T, Bayuaji H, et al. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis. Sci Rep. 2024;14(1):8229.
CR  - 33-	Mansour A, Noori M, Hakemi MS, Haghgooyan Z, Mohajeri-Tehrani MR, Mirahmad M, et al. Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome. BMC Endocr Disord. 2024;24(1):201.
CR  - 34-	Carmina E, Longo RA. Increased prevalence of elevated DHEAS in PCOS women with non-classic (B or C) phenotypes: a retrospective analysis in patients aged 20 to 29 years. Cells. 2022;11(20):3255.
CR  - 35-	Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.
CR  - 36-	Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030.
CR  - 37-	Amisi CA. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022;13(3):129-38.
CR  - 38-	Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16(1):9.
CR  - 39-	Wen X, Wang L, Bai E. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1370578.
UR  - https://doi.org/10.16899/jcm.1794476
L1  - https://dergipark.org.tr/en/download/article-file/5289250
ER  -